TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06482034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine
Description: N-acetyl cysteine sachets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine
Description: N-acetyl cysteine sachets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine
Description: N-acetyl cysteine sachets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc sulfate
Description: zinc sulfate capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc sulfate
Description: zinc sulfate capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc sulfate
Description: zinc sulfate capsules
Study: NCT04162431

Intervention type: DIAGNOSTIC_TEST
Intervention: FNA biopsy
Description: a fine needle aspiration (FNA) biopsy will be taken

Intervention type: DIAGNOSTIC_TEST
Intervention: FNA biopsy
Description: a fine needle aspiration (FNA) biopsy will be taken

Intervention type: DIAGNOSTIC_TEST
Intervention: FNA biopsy
Description: a fine needle aspiration (FNA) biopsy will be taken

Intervention type: DIAGNOSTIC_TEST
Intervention: FNA biopsy
Description: a fine needle aspiration (FNA) biopsy will be taken

Intervention type: DIAGNOSTIC_TEST
Intervention: FNA biopsy
Description: a fine needle aspiration (FNA) biopsy will be taken

Intervention type: DIAGNOSTIC_TEST
Intervention: histopathology and cytology
Description: Histopathology and cytology will be performed on the samples

Intervention type: DIAGNOSTIC_TEST
Intervention: histopathology and cytology
Description: Histopathology and cytology will be performed on the samples

Intervention type: DIAGNOSTIC_TEST
Intervention: histopathology and cytology
Description: Histopathology and cytology will be performed on the samples

Intervention type: DIAGNOSTIC_TEST
Intervention: histopathology and cytology
Description: Histopathology and cytology will be performed on the samples

Intervention type: DIAGNOSTIC_TEST
Intervention: histopathology and cytology
Description: Histopathology and cytology will be performed on the samples
Study: NCT06207097

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physiotherapy techniques
Description: Dry neeling: invasive physiotherapy technique where an acupuncture needle is used on painful points Elastic taping: physiotherapy technique where elastic bandage is used on the skin Exercise program: physical exercise prescription

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physiotherapy techniques
Description: Dry neeling: invasive physiotherapy technique where an acupuncture needle is used on painful points Elastic taping: physiotherapy technique where elastic bandage is used on the skin Exercise program: physical exercise prescription
Study: NCT06218537

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Test group
Description: Contains protease from KREON capsules, activated by adding sodium bicarbonate.
Study: NCT06482034

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: saline mouth wash
Description: saline mouth wash
Study: NCT05326464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10mg
Description: 10 mg given orally twice daily until evidence of progression, intolerance of treatment, withdrawal of consent, or death.
Study: NCT06236022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: at a dose of 2 mg once daily
Study: NCT05403866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LT3001 Drug Product
Description: Administered by intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by intravenous infusion
Study: NCT05881616

Intervention type: OTHER
Intervention: Specimen samples and baseline data collection
Description: The remaining serum samples from routine blood tests of subjects will be collected (without additional blood collection), with a serum sample size of approximately 1 mL per subject. The samples will be pre-processed and stored at ultra-low temperatures. At the same time, clinical baseline data of subjects will be collected from outpatient or inpatient medical records, including but not limited to age, height, weight, blood pressure, and gestational age.

Intervention type: OTHER
Intervention: Specimen samples and baseline data collection
Description: The remaining serum samples from routine blood tests of subjects will be collected (without additional blood collection), with a serum sample size of approximately 1 mL per subject. The samples will be pre-processed and stored at ultra-low temperatures. At the same time, clinical baseline data of subjects will be collected from outpatient or inpatient medical records, including but not limited to age, height, weight, blood pressure, and gestational age.

Intervention type: OTHER
Intervention: Specimen samples and baseline data collection
Description: The remaining serum samples from routine blood tests of subjects will be collected (without additional blood collection), with a serum sample size of approximately 1 mL per subject. The samples will be pre-processed and stored at ultra-low temperatures. At the same time, clinical baseline data of subjects will be collected from outpatient or inpatient medical records, including but not limited to age, height, weight, blood pressure, and gestational age.
Study: NCT06218537

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Control group
Description: Contains only sodium bicarbonate.
Study: NCT04657588

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Navina anal insert
Description: The Navina anal device is a single-use, pre-lubricated, liquid-filled rectal insert with a plastic applicator. The insert is filled with liquid mineral oil. The primary advantage of this new instrument is the fact that the liquid-filled insert will move and adapt as the fluid is transferred throughout the device making it easy to insert/remove and comfortable to wear. The design is intended to adjust to the contours of the individual anatomy to prevent leakage.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Care as usual
Description: Care as usual means participants are to continue their usual treatment for FI, like they would if they would not have participated in this study.
Study: NCT06501378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1/PD-L1 inhibitor plus chemotherapy
Description: Active brain metastases patients will receive PD-L1/PD-1 inhibitors and chemotherapy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SRT/WBRT
Description: Active brain metastases (BM) patients will receive stereotactic radiotherapy (SRT) and whole brain radiation therapy (WBRT) according to their BM condition.
Study: NCT03674320

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone Enanthate
Description: Testosterone Enanthate (25 mg women, 100mg men) will be given via intramuscular injection at study week 2, 3, 6, 7, 10 and 11.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Injection (saline) will be given via intramuscular injection at study week 2, 3, 6, 7, 10 and 11.
Study: NCT06576245

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Quantum Molecular Resonance (QMR) Therapy
Description: Quantum Molecular Resonance (QMR) therapy will be administered using the RexonEye® device (Resono Ophthalmic, Trieste, Italy). The device delivers low-intensity, high-frequency electrical waves ranging from 4-64 MHz through specialized contact electrodes. Participants will receive 4 QMR treatment sessions over 6 weeks. Each session lasts for 20 minutes, with a 30-second alternation between the eyes. The goal of QMR therapy is to stimulate cellular regeneration and improve tear production by targeting the lacrimal gland.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intense Pulsed Light (IPL) Therapy
Description: Intense Pulsed Light (IPL) therapy will be performed using the OptiLIGHT® device (Lumenis Be Ltd., Yokneam, Israel). IPL treatment involves the application of high-intensity, non-coherent, polychromatic light within the 500 to 1200 nm wavelength spectrum. Participants will receive 3 IPL sessions over 6 weeks, with sessions targeting the periocular area and upper eyelids to improve meibomian gland function. Each session includes the application of 50 light pulses to the periocular area and upper eyelids using specified parameters (e.g., fluence 14 J/cm² for the periocular area, fluence 11 J/cm² for the upper eyelids).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tear Substitute Treatment (Supportive Therapy)
Description: All participants will also receive supportive therapy with tear substitutes throughout the study period. This includes:~Idroflog® (0.2% Hyaluronic Acid with 0.001% Hydrocortisone): Applied 3 times per day.~VisuXL gel® (Cross-linked Carboxymethyl Cellulose with Coenzyme Q10): Applied once a day.~Artelac® Nighttime Gel (0.24% Sodium Hyaluronate with Carbomer): Applied before sleeping. These tear substitutes are intended to provide symptomatic relief and support tear film stability during the treatment period.
Study: NCT06340620

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic ultrasound examination
Description: Endoscopic ultrasound examination will be performed.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic ultrasound examination
Description: Endoscopic ultrasound examination will be performed.
Study: NCT05622669

Intervention type: OTHER
Intervention: Observational
Description: Sensed and lived experience data from all groups without a specific behavioural or drug intervention

Intervention type: OTHER
Intervention: Observational
Description: Sensed and lived experience data from all groups without a specific behavioural or drug intervention

Intervention type: OTHER
Intervention: Observational
Description: Sensed and lived experience data from all groups without a specific behavioural or drug intervention

Intervention type: OTHER
Intervention: Observational
Description: Sensed and lived experience data from all groups without a specific behavioural or drug intervention
Study: NCT06471205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-B01D1
Description: Administration by intravenous infusion on D1 and D8, or D1 for a cycle of 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 Monoclonal Antibody
Description: Administration by intravenous infusion for a cycle of 3 weeks (Q3W).
Study: NCT05110885

Intervention type: OTHER
Intervention: Questionnaire
Description: A questionnaire prepared by the researchers will be presented to the group.
Study: NCT04868266

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: end tidal carbon dioxide monitoring
Description: We will monitor end tidal carbon dioxide with capnography during minimal sedation
Study: NCT05895266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-903
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-903
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Oral Liquid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Oral Liquid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Oral Liquid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Oral Liquid
Study: NCT06088264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986322
Description: Specified dose on specified days.
Study: NCT05741801

Intervention type: OTHER
Intervention: interviews
Description: observations of healthcare professionals working in hospitals (outreach/sepsis team), one-on-one interviews with healthcare professionals, and focus groups or interviews with ex-patients/family members.

Intervention type: OTHER
Intervention: interviews
Description: observations of healthcare professionals working in hospitals (outreach/sepsis team), one-on-one interviews with healthcare professionals, and focus groups or interviews with ex-patients/family members.
Study: NCT06241274

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moxibustion
Description: Subjects received moxibustion covering Shenque, Zhonggong, Guanyuan, and Qihai for 30 minutes every day for 14 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Symptomatic supportive treatment
Description: Symptomatic supportive treatment.
Study: NCT05557045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JZP815
Description: JZP815 will be administered as oral capsules to participants BID approximately 12 hours apart, in the morning and in the evening. QD dosing may also be investigated, if supported by PK data.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JZP815
Description: JZP815 will be administered as oral capsules to participants BID approximately 12 hours apart, in the morning and in the evening. QD dosing may also be investigated, if supported by PK data.
Study: NCT04991168

Intervention type: OTHER
Intervention: Questionnaire
Description: Two questionnaires used to assess the state of knowledge and practices in oral health. An oral assessment will be carried out for voluntary patients.
Study: NCT05377580

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Period 1 IBI112 Placebo
Description: Intravenous Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period 1 IBI112 Placebo
Description: Intravenous Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period 2 IBI112 dose 3
Description: Subcutaneous injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period 1 IBI112 dose 1
Description: Intravenous Injection
Study: NCT04215679

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Three-dimensional immersive virtual reality application
Description: In this group, individuals will be included in a game program that will last for 3 days a week for a total of 6 weeks and 45 minutes a day. Individuals will use the IVR to rehabilitate functions that are frequently used in daily life through task-oriented games. The IVR device will be placed on the head of the individual by closing the eyes of the individual and the Leap Motion device will be used to enable individuals to see their own hands in a virtual reality environment. In order to ensure the safety of individuals, practices shall be carried out with the individual sitting in the chair and leaning against the back. A total of 3 different games will be used for upper extremity function, each game will be 15 minutes and the total session time will be 45 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Motor imagery
Description: Motor imagery will be performed with the eyes closed. In addition, for the safety of the individual, the individual will sit comfortably in a chair in a quiet environment and sit back. In the motor imagery group, individuals will be shown videos of the 3 games for 2 times in the IVR group and will be asked to imagine that they perform the same functions in the IVR games. The motor imagery will be 3 days a week for a total of 6 weeks and 45 minutes per day (including rest periods).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy
Description: Individuals in this group will be randomly recruited from hospitalized stroke volunteers. Since these individuals receive routine rehabilitation 5 days a week, they will be evaluated at the beginning and end of 18 sessions over a total period of 6 weeks. Conventional physiotherapy will include normal joint movements, muscle strengthening exercises, balance and mobility exercises, and exercises to improve daily life activity.
Study: NCT06441565

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fruquintinib
Description: A treatment cycle of 4 weeks, with 4 mg orally once daily for 3 weeks, followed by a 1-week break

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: A treatment cycle of 4 weeks, with 4 mg orally once daily for 3 weeks, followed by a 1-week break

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: 2.8 g/m² (400mg bolus + 2.4g/m² continuous infusion) given every 2 weeks through hepatic arterial infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m² given every 2 weeks through hepatic arterial infusion
Study: NCT04517006

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-focused acts
Description: Completion of daily acts for personal enjoyment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prosocial acts
Description: Completion of daily acts for the benefit of others.
Study: NCT05377580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period 1 IBI112 dose 2
Description: Intravenous Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period 2 IBI112 dose 4
Description: Intravenous Injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Period 2 IBI112 Placebo
Description: Subcutaneous injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period 2 IBI112 Placebo
Description: Subcutaneous injections
Study: NCT06429176

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPL84
Description: SPL84 solution for nebulization

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution for nebulization
Study: NCT05414591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP16001 drug A
Description: 1 tablet, Oral, once daily single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP16001 drug A
Description: 1 tablet, Oral, once daily single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP16001 drug B
Description: 3 tablet, Oral, once daily single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP16001 drug B
Description: 3 tablet, Oral, once daily single dose
Study: NCT05372068

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Concrete household floor
Description: Household soil floors will be replaced with concrete floors
Study: NCT05736211

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Organization-level Youth Engagement prevention strategy
Description: Systematically incorporating Youth Engagement into prevention efforts in a community setting
Study: NCT05052801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bemarituzumab
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6
Description: mFOLFOX6 administered as a combination of oxaliplatin and leucovorin as IV infusions. 5-FU administered as bolus followed by additional administration as IV infusion.
Study: NCT05034211

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Programmed intermittent bolus epidural
Description: one arm will receive programmed intermittent boluses of local anesthetic via the epidural catheter on fixed time intervals. Standard 27G Tuohy needle epidural set with epidural catheter insertion on L2-L3 site, with the patient either sitting or in the lateral decubitus position will be used. Local injection with 6 ml lidocaine 2% will be performed before the insertion of the epidural needle

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Provider administered analgesia on patient request
Description: one arm will receive bolus of local anesthetic via the catheter upon patient request. Standard 27G Tuohy needle epidural set with epidural catheter insertion on L2-L3 site, with the patient either sitting or in the lateral decubitus position will be used. Local injection with 6 ml lidocaine 2% will be performed before the insertion of the epidural needle
Study: NCT05052801

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFOX6
Description: mFOLFOX6 administered as a combination of oxaliplatin and leucovorin as IV infusions. 5-FU administered as bolus followed by additional administration as IV infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: IV infusion
Study: NCT06084338

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic ablative radiotherapy
Description: Metastasis directed
Study: NCT05028582

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARQ-154 Foam 0.3%
Description: ARQ-154 Foam 0.3%
Study: NCT06084338

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic ablative radiotherapy
Description: Metastasis directed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pluvicto
Description: PSMA targeted radiopharmaceutical therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pluvicto
Description: PSMA targeted radiopharmaceutical therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topical testosterone
Description: Topical testosterone 1.62% gel
Study: NCT04883749

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Cycle (q28d): Acalabrutinib p.o.100 mg twice daily (BID)
Study: NCT06116903

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood sampling for testing of the detection of molecular abnormalities in exosomes of glial tumors
Study: NCT06641869

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: procyanidin C1
Description: Proprietarily extracted procyanidin C1

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cellumiva
Description: Cellumiva is a novel senolytic complex blend invented by Mrs. Patricia Mayer. It's a complext of grape seed extract(its key active component later identified asPCC1), Pterostilbene and Spermidine.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06636669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Culturelle probiotic, one capsule daily to start following SOC surgical treatment for PJI during the initial 6 weeks of SOC antibiotic treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard of care (SOC) treatment includes surgery and antimicrobials.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Standard of care (SOC) treatment includes surgery and antimicrobials.